Alternatively, the new hepatitis C therapies such as sofosbuvir, ledipasvir, and daclatasvir, which are not known to be affected by the mutations in IFNL3 and IFNL4 genes, can be used (64). The gene discussed is IFNL4; the disease is hepatitis C virus infection.